1
|
Kim C, Lv G, Lee JS, Jung BC, Masuda-Suzukake M, Hong CS, Valera E, Lee HJ, Paik SR, Hasegawa M, Masliah E, Eliezer D, Lee SJ. Exposure to bacterial endotoxin generates a distinct strain of α-synuclein fibril. Sci Rep 2016; 6:30891. [PMID: 27488222 PMCID: PMC4973277 DOI: 10.1038/srep30891] [Citation(s) in RCA: 100] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Accepted: 07/12/2016] [Indexed: 11/09/2022] Open
Abstract
A single amyloidogenic protein is implicated in multiple neurological diseases and capable of generating a number of aggregate "strains" with distinct structures. Among the amyloidogenic proteins, α-synuclein generates multiple patterns of proteinopathies in a group of diseases, such as Parkinson disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). However, the link between specific conformations and distinct pathologies, the key concept of the strain hypothesis, remains elusive. Here we show that in the presence of bacterial endotoxin, lipopolysaccharide (LPS), α-synuclein generated a self-renewable, structurally distinct fibril strain that consistently induced specific patterns of synucleinopathies in mice. These results suggest that amyloid fibrils with self-renewable structures cause distinct types of proteinopathies despite the identical primary structure and that exposure to exogenous pathogens may contribute to the diversity of synucleinopathies.
Collapse
Affiliation(s)
- Changyoun Kim
- Department of Biomedical Sciences, Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, Korea
- Departments of Neurosciences and Pathology, School of Medicine, University of California, San Diego, La Jolla, CA, USA
| | - Guohua Lv
- Department of Biochemistry, Weill Cornell Medical College, NY, USA
| | - Jun Sung Lee
- Department of Biomedical Sciences, Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Byung Chul Jung
- Department of Biomedical Sciences, Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, Korea
- Department of Biomedical Laboratory Science, College of Health Science, Yonsei University, Wonju, Korea
| | - Masami Masuda-Suzukake
- Department of Neuropathology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| | - Chul-Suk Hong
- School of Chemical and Biological Engineering, College of Engineering, Seoul National University, Seoul, Korea
| | - Elvira Valera
- Departments of Neurosciences and Pathology, School of Medicine, University of California, San Diego, La Jolla, CA, USA
| | - He-Jin Lee
- Department of Anatomy, School of Medicine, Konkuk University, Seoul, Korea
| | - Seung R. Paik
- School of Chemical and Biological Engineering, College of Engineering, Seoul National University, Seoul, Korea
| | - Masato Hasegawa
- Department of Neuropathology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| | - Eliezer Masliah
- Departments of Neurosciences and Pathology, School of Medicine, University of California, San Diego, La Jolla, CA, USA
| | - David Eliezer
- Department of Biochemistry, Weill Cornell Medical College, NY, USA
| | - Seung-Jae Lee
- Department of Biomedical Sciences, Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, Korea
| |
Collapse
|
2
|
Wang B, Guo C, Lou Z, Xu B. Following the aggregation of human prion protein on Au(111) surface in real-time. Chem Commun (Camb) 2015; 51:2088-90. [DOI: 10.1039/c4cc09209k] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The mechanism of prion protein (PrP) aggregation on an Au(111) surface was determined by combining AFM real-time imaging with molecular dynamics and docking simulations.
Collapse
Affiliation(s)
- Bin Wang
- Single Molecule Study Laboratory
- Faculty of Engineering and Nanoscale Science and Engineering Center
- University of Georgia
- Athens
- USA
| | - Cunlan Guo
- Single Molecule Study Laboratory
- Faculty of Engineering and Nanoscale Science and Engineering Center
- University of Georgia
- Athens
- USA
| | - Zhichao Lou
- Single Molecule Study Laboratory
- Faculty of Engineering and Nanoscale Science and Engineering Center
- University of Georgia
- Athens
- USA
| | - Bingqian Xu
- Single Molecule Study Laboratory
- Faculty of Engineering and Nanoscale Science and Engineering Center
- University of Georgia
- Athens
- USA
| |
Collapse
|
3
|
Prion protein-specific antibodies-development, modes of action and therapeutics application. Viruses 2014; 6:3719-37. [PMID: 25275428 PMCID: PMC4213558 DOI: 10.3390/v6103719] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Revised: 09/22/2014] [Accepted: 09/23/2014] [Indexed: 12/21/2022] Open
Abstract
Prion diseases or Transmissible Spongiform Encephalopathies (TSEs) are lethal neurodegenerative disorders involving the misfolding of the host encoded cellular prion protein, PrPC. This physiological form of the protein is expressed throughout the body, and it reaches the highest levels in the central nervous system where the pathology occurs. The conversion into the pathogenic isoform denoted as prion or PrPSc is the key event in prion disorders. Prominent candidates for the treatment of prion diseases are antibodies and their derivatives. Anti-PrPC antibodies are able to clear PrPSc from cell culture of infected cells. Furthermore, application of anti-PrPC antibodies suppresses prion replication in experimental animal models. Major drawbacks of immunotherapy are immune tolerance, the risks of neurotoxic side effects, limited ability of compounds to cross the blood-brain barrier and their unfavorable pharmacokinetic. The focus of this review is to recapitulate the current understanding of the molecular mechanisms for antibody mediated anti-prion activity. Although relevant for designing immunotherapeutic tools, the characterization of key antibody parameters shaping the molecular mechanism of the PrPC to PrPSc conversion remains elusive. Moreover, this review illustrates the various attempts towards the development of anti-PrP antibody compounds and discusses therapeutic candidates that modulate PrP expression.
Collapse
|
4
|
Botto L, Cunati D, Coco S, Sesana S, Bulbarelli A, Biasini E, Colombo L, Negro A, Chiesa R, Masserini M, Palestini P. Role of lipid rafts and GM1 in the segregation and processing of prion protein. PLoS One 2014; 9:e98344. [PMID: 24859148 PMCID: PMC4032283 DOI: 10.1371/journal.pone.0098344] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2013] [Accepted: 05/01/2014] [Indexed: 12/04/2022] Open
Abstract
The prion protein (PrPC) is highly expressed within the nervous system. Similar to other GPI-anchored proteins, PrPC is found in lipid rafts, membrane domains enriched in cholesterol and sphingolipids. PrPC raft association, together with raft lipid composition, appears essential for the conversion of PrPC into the scrapie isoform PrPSc, and the development of prion disease. Controversial findings were reported on the nature of PrPC-containing rafts, as well as on the distribution of PrPC between rafts and non-raft membranes. We investigated PrPC/ganglioside relationships and their influence on PrPC localization in a neuronal cellular model, cerebellar granule cells. Our findings argue that in these cells at least two PrPC conformations coexist: in lipid rafts PrPC is present in the native folding (α-helical), stabilized by chemico-physical condition, while it is mainly present in other membrane compartments in a PrPSc-like conformation. We verified, by means of antibody reactivity and circular dichroism spectroscopy, that changes in lipid raft-ganglioside content alters PrPC conformation and interaction with lipid bilayers, without modifying PrPC distribution or cleavage. Our data provide new insights into the cellular mechanism of prion conversion and suggest that GM1-prion protein interaction at the cell surface could play a significant role in the mechanism predisposing to pathology.
Collapse
Affiliation(s)
- Laura Botto
- Department of Health Science - Medical School, University of Milano-Bicocca, Monza, Italy
- * E-mail:
| | - Diana Cunati
- Department of Health Science - Medical School, University of Milano-Bicocca, Monza, Italy
| | - Silvia Coco
- Department of Health Science - Medical School, University of Milano-Bicocca, Monza, Italy
| | - Silvia Sesana
- Department of Health Science - Medical School, University of Milano-Bicocca, Monza, Italy
| | - Alessandra Bulbarelli
- Department of Health Science - Medical School, University of Milano-Bicocca, Monza, Italy
| | - Emiliano Biasini
- Department of Neuroscience, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | - Laura Colombo
- Department of Molecular Biochemistry and Pharmacology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | - Alessandro Negro
- Department of Biomedical Sciences, University of Padova, Padova, Italy
| | - Roberto Chiesa
- Department of Neuroscience, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | - Massimo Masserini
- Department of Health Science - Medical School, University of Milano-Bicocca, Monza, Italy
| | - Paola Palestini
- Department of Health Science - Medical School, University of Milano-Bicocca, Monza, Italy
| |
Collapse
|
5
|
Single-chain fragment variable passive immunotherapies for neurodegenerative diseases. Int J Mol Sci 2013; 14:19109-27. [PMID: 24048248 PMCID: PMC3794823 DOI: 10.3390/ijms140919109] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2013] [Revised: 08/29/2013] [Accepted: 08/30/2013] [Indexed: 01/26/2023] Open
Abstract
Accumulation of misfolded proteins has been implicated in a variety of neurodegenerative diseases including prion diseases, Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD). In the past decade, single-chain fragment variable (scFv) -based immunotherapies have been developed to target abnormal proteins or various forms of protein aggregates including Aβ, SNCA, Htt, and PrP proteins. The scFvs are produced by fusing the variable regions of the antibody heavy and light chains, creating a much smaller protein with unaltered specificity. Because of its small size and relative ease of production, scFvs are promising diagnostic and therapeutic reagents for protein misfolded diseases. Studies have demonstrated the efficacy and safety of scFvs in preventing amyloid protein aggregation in preclinical models. Herein, we discuss recent developments of these immunotherapeutics. We review efforts of our group and others using scFv in neurodegenerative disease models. We illustrate the advantages of scFvs, including engineering to enhance misfolded conformer specificity and subcellular targeting to optimize therapeutic action.
Collapse
|